Hospices Civils de Lyon, Hematology Department, Lyon-Sud University Hospital , Pierre Bénite, France.
Expert Rev Hematol. 2020 Jun;13(6):619-643. doi: 10.1080/17474086.2020.1758058. Epub 2020 May 13.
Acute myeloid leukemia (AML) is a disease mainly seen in the elderly, for which treatment is undergoing rapid changes. Although recent studies have supported the survival benefit of induction chemotherapy in fit patients and that of hypomethylating agents (HMAs) in non-induction candidates, treatment of this patient age population remains a significant challenge for the treating oncologist.
In this review, we will examine effectiveness and safety outcomes of upcoming novel treatment strategies in elderly (≥60 years old) patients with AML, highlight the current literature and ongoing trials able to maximize therapeutic options in this heterogeneous patient population.
Current developments including new chemotherapeutic strategies and combinations of HMAs with novel drugs targeting epigenetic or immunomodulatory pathways are underway to improve patient survival and quality of life.
急性髓系白血病（AML）主要见于老年人，其治疗正在迅速变化。尽管最近的研究支持诱导化疗在合适患者中的生存获益，以及低甲基化剂（HMAs）在非诱导候选者中的获益，但对于治疗肿瘤学家来说，治疗该年龄人群仍然是一个重大挑战。
在这篇综述中，我们将研究新型治疗策略在老年（≥60 岁）AML 患者中的有效性和安全性结果，强调当前文献和正在进行的试验，以最大限度地增加该异质患者人群的治疗选择。
目前正在开展包括新的化疗策略以及 HMAs 与靶向表观遗传或免疫调节途径的新型药物联合的新进展，以提高患者的生存率和生活质量。
